BackSCIENCE_HEALTH
Hope for pancreatic cancer as new drug, daraxonrasib, shows promise
The article outlines the long struggle to target KRAS in pancreatic cancer, explains how daraxonrasib works by indirectly inhibiting RAS proteins, and presents phase 3 results suggesting substantial tumor reduction and disease control with manageable side effects. It notes the findings were reported at the AACR meeting in San Diego in April 2026 and discusses the potential impact on treatment options.
Why It Matters
If confirmed by peer-reviewed data, daraxonrasib could broaden treatment choices for pancreatic cancer and other RAS-driven cancers, addressing a historically undruggable target.
Timeline
6 Events
May 9, 2026: Article publication on the trial findings
May 9, 2026
The article reporting on daraxonrasib's phase 3 results and the ensuing excitement for pancreatic cancer treatment was published.
May 8, 2026: publication note linked to daraxonrasib
May 8, 2026
The article notes a publication related to daraxonrasib appeared on May 8, 2026 at 07:15 am IST.
April 22, 2026: AACR meeting in San Diego concluded
April 22, 2026
The AACR annual meeting in San Diego concluded after running from April 17–22, 2026.
April 17, 2026: Phase 3 results presented at AACR meeting
April 17, 2026
Phase 3 trial results for daraxonrasib were presented at the American Association for Cancer Research annual meeting in San Diego, indicating the drug reduced tumours in 51% of pancreatic cancer patients and achieved disease control in 97%.
June 2024: Revolution Medicines targets RAS with daraxonrasib
June 2024
Revolution Medicines announced RMC-6236, later renamed daraxonrasib, a molecule designed to inhibit multiple RAS variants by indirectly locking KRAS in an inactive state via binding to cyclophilin-A.
1988 KRAS mutation discovery highlighted in pancreatic cancer
1988
A landmark paper in Cell reported that KRAS mutations occur in around 95% of pancreatic cancers, underscoring KRAS as a central driver of the disease.